Linago 5 mg (Tablet)
Unit Price: ৳ 15.00 (3 x 10: ৳ 450.00)
Strip Price: ৳ 150.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Linagliptin |
| Company | Medicon pharmaceuticals ltd |
Title
- Linago 5 mg Tablet
Categories
- Medicine
- Diabetes Care
- Healthcare
Description
- Linago 5 mg Tablet is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults.
Dosage
- Linagliptin 5 mg once daily
Administration
- If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly.
Special Considerations
- Lower dose of the sulphonylurea may be considered when used in combination with a sulfonylurea to reduce the risk of hypoglycaemia.
Pharmacology
- Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4).
- Increases concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner.
Interaction
- Weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4.
- No clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
Side Effects
- May include hypoglycaemia, nasopharyngitis, cough, and pancreatitis in combination with metformin and sulfonylurea.
Pregnancy & Lactation
- Pregnancy category B. Use during pregnancy only if clearly needed.
Precautions & Warnings
- Hypersensitivity to the active substance or to any of the excipients.
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Keep in a dry place away from light and heat. Keep out of the reach of children.
Chemical Structure
- Molecular Formula: C25H28N8O2
Indications
- As monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment.
Mode of Action
- Increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.
Renal Impairment
- No dose adjustment required. Can be taken with or without a meal at any time of the day.
Hypersensitivity
- Hypersensitivity to the active substance or to any of the excipients.
Clinical Studies
- Low risk for clinically meaningful interactions by other medicinal products.
Usability
- Should be taken at the same time every day for consistent effect.
Adverse Reactions
- Possible hypoglycemia when used with other antidiabetic medicines or alcohol.
Storage Instructions
- Should be kept in its original packaging in a cool dry place.
Reminder
- Carry sugary food or fruit juice in case of hypoglycemia symptoms.
Safety Precaution
- Be careful while driving or operating machinery until the effects are known.
Monitoring
- Inform your doctor if joint pains or other symptoms occur.
Clinical Impact
- No clinically relevant effect on selected pharmacokinetics in clinical studies.
Dosage Frequency
- Should be taken in the prescribed dosage as per doctor's instructions.
Food Intake
- Should be taken after food for best results.
Instructions
- Inform your doctor if you notice any adverse symptoms or side effects.
Administration Flexibility
- May be taken with or without a meal at any time of the day.
Drug Enzyme Inhibition
- Inhibitor of DPP-4 (dipeptidyl peptidase-4) enzyme.
Ability to Cross Biological Barriers
- It is not known whether Linagliptin passes into breast milk.
Chemical Structure Image
- Link to the chemical structure image provided.
Treatment Duration
- To be continued until improvement in health conditions.
Symptom Improvement
- To be taken till the time improvement in health conditions is observed.
Medication Duration
- To be taken as long as needed for health improvement.
Special Instructions
- Keep the medication unreachable to children and pets.
Disease Management
- Therapeutic medication for the treatment of type 2 diabetes mellitus.
Family Planning
- Use during pregnancy only if clearly needed.
Breastfeeding Consideration
- It is not known whether Linagliptin passes into breast milk.
Visual Aid
- Graphic representation of the chemical structure provided.
Product Usage
- For the treatment of type 2 diabetes mellitus in adults.
Molecular Composition
- C25H28N8O2
Microbiological Properties
- No clinically relevant effect on the microbiological profile.
Instruction Adherence
- Should be taken as prescribed in the medication schedule.
Handling Precaution
- Should be kept away from light and heat sources to maintain efficacy.
Safety Information
- For best results, follow the prescribed dosage and administration instructions.
Preventive Measures
- To reduce the risk of hypoglycemia, lower dose of sulphonylurea may be considered.
Health Consideration
- Ensure the medication is stored in an appropriate and safe location.
Functional Mechanism
- Inhibits DPP-4 enzyme to improve glycemic control.
Environmental Impact
- Keep in a dry place to preserve the medication's effectiveness.
Medication Specifics
- Pharmacological details and specific benefits of Linago 5 mg Tablet.
Medication History
- Useful in the treatment history of patients with type 2 diabetes mellitus.
Usage Tip
- Should be taken at the same time every day to establish a consistent routine.
Renal Impairment Detail
- No dose adjustment required for patients with renal impairment.
Complementary Therapy Consideration
- To be used in combination with metformin and/or sulphonylurea for adequate glycaemic control.
Clinical Trial Findings
- No clinically relevant effect on the pharmacokinetics of various drugs in clinical studies.
Class Characterization
- Classified as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor.
Mechanism Insight
- Inhibits DPP-4 enzyme and increases concentrations of active incretin hormones.
Contradistinction
- Hypersensitivity to the active substance or to any of the excipients.
Compliance Aspect
- Important to comply with the prescribed dosage and administration guidelines.
Stability Factor
- Keep in a dry place away from light and heat to maintain stability.
Excretion Consideration
- It is not known whether Linagliptin passes into breast milk.
Pregnancy Recommendation
- Use during pregnancy only if clearly needed as per physician's advice.
Lactation Directive
- It is not known whether Linagliptin passes into breast milk.
User Guide
- Detailed instructions and information for users of Linago 5 mg Tablet.
Active Substance Information
- Contains Linagliptin as the active substance for diabetes management.
Medication Assurance
- Keep out of the reach of children for safety and prevention.
Patient Education
- May cause hypoglycemia when used with other antidiabetic medicines or alcohol.
Age Group Specification
- Indicated for the treatment of type 2 diabetes mellitus in adults.
Diabetes Management Tool
- A therapeutic medication aimed at improving glycaemic control in adults with type 2 diabetes mellitus.